Simple nudge: mailed reminders and navigators may catch liver cancer earlier
NCT ID NCT06635694
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepatocellular carcinoma. The goal is to see if these simple support tools help catch liver cancer at an earlier, more treatable stage compared to usual care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that simple support like mailed reminders and a navigator can help more high-risk patients get regular liver cancer screening, potentially catching cancer earlier.
- What could go wrong
- This is a behavioral study, not a drug trial. Even if attendance improves, it may not lead to earlier cancer detection or better survival. Results may not apply to all healthcare settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEP B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?